Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rockwell Automation (ROK) vs Viatris Inc (VTRS) Price & Performance

Rockwell AutomationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Rockwell Automation vs Viatris Inc — how do they compare? Rockwell Automation trades at $439.02 (market cap $48.21B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Rockwell Automation is far larger — about 2.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and Viatris Inc for 57 Days on average.

ROKVTRS
Market Cap
$48.21B$20.03B
Volume
953,34214,109,977
Sector
IndustrialsHealth
52-Week High
$495.08$18.27
52-Week Low
$333.75$9.74
Typical Hold Time
74 Days57 Days
Enterprise Value
$51.34B$32.15B
Dividend Yield
1.27%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rockwell Automation

Rockwell Automation (ROK) trades at $441.9, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $489.89 implying 11% upside. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending, and maintains strong profitability with a 13.38% net income margin and 34.47% ROE. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms.

ROK presents a growth opportunity driven by automation demand and digital transformation trends, but faces risks from high valuation multiples (P/E 41.38) and cyclical industrial spending. Analyst sentiment is mixed with 68% hold ratings, reflecting caution amid solid fundamentals. Investors should weigh earnings consistency against premium pricing.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ROK
0% Buy100% Sell
Avg holding period · 74 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Rockwell Automation

Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.

Read more on ROK →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →